title: Developing good scientific publishing practices: one pharmaceutical company's perspective.
abstract: BACKGROUND
  The scientific publishing practices of the pharmaceutical industry have been heavily criticized in recent years due to the inherent conflict of interest that arises when a pharmaceutical company publishes findings around its own drugs.
  
  
  METHODS
  Eli Lilly and Company ('Lilly') strives for transparency in its day-to-day activities, and, here, shares its principles, policies and practices on publishing "Lilly-sponsored" research.
  
  
  RESULTS
  A conflict of interest does not necessarily equate to biased presentation of research findings, and operating a successful, for-profit business and maintaining a focus on improving the health of patients are not mutually exclusive goals. There is, however, potential for bias, and it is incumbent upon a for-profit to develop publication principles, policies and practices to address this. To this end, Lilly's Principles of Medical Research states that 'Lilly discloses publicly all medical research results that are important to patients, healthcare providers or payers--whether favorable or unfavorable to a Lilly product--in an accurate, objective, and balanced manner ...' The preparation of publications of Lilly-sponsored research involves close collaboration between external (i.e., academic or otherwise non-industry employees) and Lilly scientific researchers (including scientific writers), with both serving as authors. Lilly does not support 'ghost' or 'guest' authorship. Authorship is not just recognition of contribution but also public acknowledgement of responsibility for content, and all authors are expected to take an active role in developing the manuscript in line with the International Committee of Medical Journal Editors-based authorship requirements. This is agreed to by authors before the manuscript is started. Lilly provides external authors with access to the trial data for manuscript development. Lilly does not pay external authors for their involvement in manuscript development. Scientific writers at Lilly, often with advanced scientific degrees, offer both scientific and writing expertise in manuscript development and play a project management role. Their role is transparent, and they are included as authors or appropriately acknowledged.
  
  
  CONCLUSIONS
  Lilly has an ongoing commitment to appropriate publishing practices. Sharing company publication principles, policies and practices is one way to demonstrate this commitment and encourage and facilitate open dialogue among all those involved in drug development.
authors.affiliation: Eli Lilly and Company, Indianapolis, IN 46285, USA. Dowsettsa@lilly.com
authors.forename: Sherie A
authors.initials: SA
authors.lastname: Dowsett
authors.forename: Luann E
authors.initials: LE
authors.lastname: Van Campen
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Bednar
mesh_terms: D001319:Authorship; D035843:Biomedical Research; D016265:Conflict of Interest; D004345:Drug Industry; D035081:Editorial Policies; D020452:Journalism; D017594:Publication Bias